Epzicom

HIV, Treatment Naive, HIV + 3 more
Treatment
3 FDA approvals
20 Active Studies for Epzicom

What is Epzicom

LamivudineThe Generic name of this drug
Treatment SummaryAbacavir (ABC) is a medication used to treat HIV and AIDS. It is a type of drug called a nucleoside analog reverse transcriptase inhibitor (NRTI) that works by stopping the virus from replicating. It is a synthetic carbocyclic nucleoside with an 1S, 4R absolute configuration on the cyclopentene ring. In the body, it dissociates into its active form, abacavir.
Epiviris the brand name
Epzicom Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Epivir
Lamivudine
1995
178

Approved as Treatment by the FDA

Lamivudine, otherwise called Epivir, is approved by the FDA for 3 uses which include HIV and Chronic Hepatitis B Infection .
HIV
Used to treat Human Immunodeficiency Virus Type 1 (HIV-1) Infection in combination with Abacavir
Chronic Hepatitis B Infection
HIV

Effectiveness

How Epzicom Affects PatientsAbacavir is a drug used to treat HIV-1 infections. It works by blocking the virus from making copies of itself. Tests have shown that Abacavir can reduce the amount of virus in the body by 50% in concentrations ranging from 0.28 mcg/mL to 5.8 mcg/mL. Abacavir can also be used in combination with other drugs such as zidovudine, nevirapine and amprenavir to increase its effectiveness. When used together with the drugs didanosine, emtricitabine, lamivudine, stavudine
How Epzicom works in the bodyAbacavir is a drug used to treat HIV. It works by blocking a protein called reverse transcriptase, which is responsible for replicating the virus. Inside the body, abacavir is changed into an active form that competes with the natural DNA building block dGTP. When abacavir is used instead, it prevents the virus from making new copies of itself.

When to interrupt dosage

The quantity of Epzicom is contingent upon the determined medical condition. The amount likewise fluctuates as per the technique of delivery (e.g. Oral or Tablet, film coated - Oral) featured in the table beneath.
Condition
Dosage
Administration
HIV
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Solution, Tablet, film coated - Oral, Solution - Oral, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral
Treatment Naive
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Solution, Tablet, film coated - Oral, Solution - Oral, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral
HIV
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Solution, Tablet, film coated - Oral, Solution - Oral, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral
Anti-Retroviral Agents
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Solution, Tablet, film coated - Oral, Solution - Oral, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral
Chronic Hepatitis B Infection
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Solution, Tablet, film coated - Oral, Solution - Oral, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral
treatment failure
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Solution, Tablet, film coated - Oral, Solution - Oral, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral

Warnings

Epzicom has three contraindications and it should not be administered in cases of the following conditions in the table.There are 20 known major drug interactions with Epzicom.
Common Epzicom Drug Interactions
Drug Name
Risk Level
Description
Aclidinium
Minor
Lamivudine may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine
Minor
Lamivudine may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Albutrepenonacog alfa
Minor
Lamivudine may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Allylestrenol
Minor
Lamivudine may decrease the excretion rate of Allylestrenol which could result in a higher serum level.
Almasilate
Minor
Lamivudine may decrease the excretion rate of Almasilate which could result in a higher serum level.
Epzicom Toxicity & Overdose RiskAt least 10% of adults in HIV-1 clinical trials have reported feeling moderate levels of nausea, headaches, tiredness, vomiting, and disordered sleep. Abacavir is known to cause serious allergic reactions in some people with the HLA-B*57:01 gene. Testing for this gene is recommended by the FDA before beginning treatment. Research has also found that rats and mice who take abacavir may experience heart damage.

Epzicom Novel Uses: Which Conditions Have a Clinical Trial Featuring Epzicom?

A total of 43 active studies are being conducted to assess the efficacy of Epzicom in managing HIV (Human Immunodeficiency Virus).
Condition
Clinical Trials
Trial Phases
HIV
155 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1
HIV
39 Actively Recruiting
Phase 2, Phase 3, Phase 1, Early Phase 1, Not Applicable, Phase 4
Chronic Hepatitis B Infection
8 Actively Recruiting
Phase 3, Phase 2, Phase 1
Treatment Naive
0 Actively Recruiting
treatment failure
0 Actively Recruiting
Anti-Retroviral Agents
0 Actively Recruiting

Epzicom Reviews: What are patients saying about Epzicom?

4.7Patient Review
4/17/2008
Epzicom for HIV
Epzicom, in conjunction with Sustiva, has been my go-to treatment since it became available. I've had undetectable viral load, high CD4 counts and good CD4/CD8 ratio while on this regimen. The only downside is the price; it's becoming more and more expensive.
4.7Patient Review
10/14/2008
Epzicom for HIV
I am taking this medication as part of my HIV treatment and it is going great! I love how easy it is to take, and it is just one of three medications I'm on. The side effects weren't bad for me either. Some levels were adjusted after a couple days and that was it. Now the only problem is that I'm always hot. Sleeping has been a challenge because of it, especially for my husband!
3Patient Review
3/23/2008
Epzicom for HIV
I started taking this medication two days ago and have experienced some side effects. I'm not sure what to do at the moment.
1Patient Review
10/18/2009
Epzicom for HIV
I had a lot of negative side effects from this medication, so I would not recommend it to others.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about epzicom

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What type of drug is Epzicom?

"Epzicom contains a combination of abacavir and lamivudine. These antiviral medicines work to prevent human immunodeficiency virus (HIV) from multiplying in your body. Epzicom is a combination medicine used to treat HIV, the virus that can cause the acquired immunodeficiency syndrome (AIDS)."

Answered by AI

How much does Epzicom cost?

"The cost for Epzicom oral tablet (600 mg-300 mg) is around $1,370 for a supply of 30 tablets. Prices may vary depending on the pharmacy you visit. This price is for cash paying customers only and does not apply to customers with insurance plans."

Answered by AI

What is Epzicom used for?

"This product contains a combination of two drugs, abacavir and lamivudine, which are used in conjunction with other HIV medications to help control the progression of HIV infection by reducing the amount of the virus in the patient's body, allowing the immune system to function more effectively."

Answered by AI

Is Epzicom generic?

"The generic version of Epzicom may be significantly cheaper compared to the brand version."

Answered by AI

Clinical Trials for Epzicom

Image of University of Alabama at Birmingham in Birmingham, United States.

Olfactory Training for HIV

18+
All Sexes
Birmingham, AL
The goal of this study is to examine two types of olfactory interventions (olfactory training vs overnight odor diffuser) in adults with HIV. The two research questions are: 1. Determine if participants find the intervention acceptable and assess feasibility of the study. 2. Determine if the intervention improves olfactory function and cognitive function. Participants will come to our office and be administered the baseline battery of questions including olfactory and cognitive performance tests. Then they will be randomized and sent home with one of the two interventions (below) in which they will engage in it for 8 weeks, after which they come back to our office for the posttest battery of questions including olfactory and cognitive performance test. 1. Olfactory Training at Home -- 4 scents in which they will smell twice a day for 8 weeks. 2. Overnight Diffuser Group -- a single scent diffuser that participants will turn on while they sleep and use for 8 weeks.
Phase < 1
Waitlist Available
University of Alabama at Birmingham
Image of Los Angeles General Medical Center in Los Angeles, United States.

Decision Support Tool for HIV Treatment

18+
All Sexes
Los Angeles, CA
This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging. In this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care. The investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.
Waitlist Available
Has No Placebo
Los Angeles General Medical CenterHayoun Lee, PhD
Image of University of North Carolina in Chapel Hill, United States.

MGD020 + MGD014 for HIV

18 - 65
All Sexes
Chapel Hill, NC
This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral medication to help expose HIV in cells to the antibodies. The study will measure the impact of study treatment on non-active HIV in cells, and how long MGD014 and MGD020 stay in the body after they are given. In this study, participants will be randomly assigned to one of three groups. All participants receive MGD014 and MGD020, given sequentially as infusions through an IV for 4 doses. Participants in one group (group A) receive only MGD014 and MGD020. Participants in another group (group B) will stop taking their ART therapy for up to 8 weeks (a temporary treatment interruption (TTI)) while receiving MGD014 and MGD020. Participants in the third group (group C) receive Vorinostat in addition to MGD014 and MGD020. Total time of participation is about 8 months and involves 13 or 18 visits, depending on group assignment.
Phase 1
Recruiting
University of North CarolinaCynthia L. Gay, MD
Have you considered Epzicom clinical trials? We made a collection of clinical trials featuring Epzicom, we think they might fit your search criteria.Go to Trials
Have you considered Epzicom clinical trials? We made a collection of clinical trials featuring Epzicom, we think they might fit your search criteria.Go to Trials
Image of UCSF in San Francisco, United States.

N-803 for HIV

18 - 70
All Sexes
San Francisco, CA
Even though HIV medicine stops the virus from making more copies of itself, the virus remains in the body by hiding inside of immune cells. This hidden virus is referred to as the "latent reservoir." Researchers on this team are studying whether stimulating the immune system can change the nature of the latent reservoir and if this could help people control HIV without the need to take regular HIV medicine. This study is testing a drug called N-803. N-803 is also known as Interleukin-15 or "IL-15", a powerful and long lasting protein that can affect the immune system by stimulating immune cells such as CD8+ T cells and natural killer (NK) cells. CD8+ T cells and NK cells are both crucial for eliminating infected cells. The drug is FDA-approved for the treatment of bladder cancer, but in this study the drug is being used experimentally for HIV.
Phase 2
Waitlist Available
UCSF
Image of Alabama CRS (Site ID: 31788) in Birmingham, United States.

Dasatinib + Quercetin for HIV

18+
All Sexes
Birmingham, AL
This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail. The study will involve 80 participants, all aged 50 or older, who have been living with HIV for at least 10 years determined to meet criteria for diagnosis of frail or prefrail and are currently on a stable antiretroviral therapy with viral suppression. Participants will be randomly assigned to one of two groups: one group will receive the D+Q treatment, and the other will receive a placebo. The treatment will be given in six cycles over 12 weeks, with participants taking the medication for two days followed by 12 days without treatment. After the 12-week treatment period, participants will be monitored for another 12 weeks to assess the long-term effects. The study aims to determine if D+Q can improve physical function and other health outcomes in this population. Randomization will be stratified by sex and age to ensure balanced groups.
Phase 2
Waitlist Available
Alabama CRS (Site ID: 31788) (+26 Sites)
Image of Yale University in New Haven, United States.

DynamiCare + Patient Navigation for Stimulant Use Disorder

18+
All Sexes
New Haven, CT
Justice-involved individuals face disproportionately high rates of stimulant use disorder and HIV, along with disrupted access to HIV treatment and prevention services like ART and PrEP. Contingency management (CM) is the most effective intervention for stimulant use, but its use in justice-involved populations has been limited by logistical and structural barriers. DynamiCare is an FDA-approved mobile app that delivers behavioral CM and has shown promise in reducing stimulant use, but its impact on HIV-related outcomes remains unknown. The RESTORE study (Recovery and Engagement for Stimulant Users on Re-entry) will evaluate whether combining DynamiCare with patient navigation (DynamiCare-plus) improves PrEP/ART initiation and reduces stimulant use among individuals recently released from justice settings. The R61 phase will assess feasibility, acceptability, and preliminary effectiveness among 40 participants. If milestones are met, the R33 phase will scale to a randomized controlled trial with 252 participants to assess effectiveness, implementation, and cost. This scalable, mobile approach has the potential to address a critical gap in care for a highly vulnerable population.
Waitlist Available
Has No Placebo
Yale University (+1 Sites)Ank Nijhawan, MD
Have you considered Epzicom clinical trials? We made a collection of clinical trials featuring Epzicom, we think they might fit your search criteria.Go to Trials